Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 2/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.31 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.31 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.31 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | STS | P08842 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5855042 | 0.96 | CYP19A1 (0.33) | PTGER2OPRM1OPRD1CYP19A1PTGER4 | |
| SCHEMBL7263350 | 0.88 | ALOX5 (0.34) | — | |
| SCHEMBL7257972 | 0.86 | PTGER2 (0.35) | PTGER2PTGER4PTGER3HTTHSD17B3 | |
| SCHEMBL7257977 | 0.84 | ALOX5 (0.34) | OPRM1CYP19A1 | |
| SCHEMBL5854340 | 0.78 | STS (0.34) | PTGER2OPRM1OPRD1CYP19A1PTGER4 | |
| SCHEMBL5854000 | 0.78 | STS (0.34) | PTGER2OPRM1OPRD1CYP19A1PTGER4 | |
| SCHEMBL5857175 | 0.78 | STS (0.34) | PTGER2OPRM1OPRD1CYP19A1PTGER4 | |
| SCHEMBL5854259 | 0.78 | STS (0.34) | PTGER2OPRM1OPRD1CYP19A1PTGER4 | |
| SCHEMBL5854573 | 0.78 | STS (0.34) | PTGER2OPRM1OPRD1CYP19A1PTGER4 | |
| SCHEMBL5856005 | 0.77 | EDNRB (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7074819-B2 | Benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA | 2004-05-27 | — | — | US | disclosed |
| US-6645951-B1 | Antiestrogens for treating breast cancer | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-11 | — | — | US | disclosed |
| EP-1087959-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065893-A1 | NOVEL BENZOPYRAN OR THIOBENZOPYRAN DERIVATIVES | C & C RESEARCH LABORATORIES (KR) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102479-A1 | Novel benzopyran or thiobenzopyran derivatives | NR5A1, SHBG, ESR2 | PTGER2 348/4885OPRM1 354/4885OPRD1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.